Candidate: TNX-2300

Category: VAX

Type: Vaccine designed to use a novel-live virus vaccine vector platform BPI3V based on bovine parainfluenza virus and the CD40-ligand, also known as CD154 or 5c8 antigen, to stimulate T cell immunity against the SARS-CoV-2 spike protein.

Status: Tonix said July 13 it signed a new preclinical research and option agreement with Kansas State University (K-State) to develop TNX-2300 a vaccine candidate to prevent COVID-19. Under the research agreement, whose value was not disclosed, K-State will advance preclinical development of a live replicating virus vaccine to protect against COVID-19 based on bovine parainfluenza virus. K-State has granted Tonix an option for an exclusive license for the clinical and commercial use of K-State’s intellectual property associated with coronavirus vaccines.

According to Tonix, testing in non-human primates showed the attenuated BPI3V to be well tolerated, infectious, immunogenic, and stable in infants and children. The vector was shown to be well suited for mucosal immunization using a nasal atomizer, but can also be delivered parenterally.

Research will be directed by Waithaka Mwangi, PhD, of K-State, the inventor of the live virus vaccine vector platform technology. TNX-2300 is Tonix’s second live viral vaccine vector platform for the prevention of COVID-19.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA